Skip to content

MESO

Mesoblast Ltd.

NASDAQ · Healthcare · Biotechnology · AU

$11.95
−10.02%
Ask drillr

Year over year

Reported trailing growth

Revenue
+602.3%
EBITDA
+24.1%
EBIT
-7.4%
EPS
+48.4%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
-87.1%
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+152.5%
EBITDA
+41.8%
EBIT
+17.5%
Net income
+43.5%
EPS
+46.4%
Free cash flow
+11.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026